Akari Therapeutics, Plc (AKTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 13.94M USD | Liabilities, Current |
| Cash and equivalents | 7.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $13.94M | $7.69M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $13.41M | $2.77M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $12.35M | $0.00 | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $15.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $17.14M | $2.71M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $20.91M | $2.58M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $19.91M | $2.60M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $9.43M | $2.25M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $8.78M | $4.18M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $6.33M | $1.31M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $3.85M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $7.18M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $13.25M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $8.15M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $9.36M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $3.79M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $14.06M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $12.32M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $12.75M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $7.82M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $5.73M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $6.27M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $2.74M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $6.15M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.92M | $5.45M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $8.28M | $15.07M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $11.85M | $28.11M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $9.14M | $30.12M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $11.71M | $34.10M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $16.99M | $9.66M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $16.55M | $61.43M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $21.12M | $68.92M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $37.80M | $78.77M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $960.00K | $2.72M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $910.00K | $4.02M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.36M | $6.22M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $52.61K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $11.36M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $13.83M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.23M | $7.66M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $3.85M | $1.10M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $2.24M | $6.00K | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $9.00K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $3.00K | (m) | (m) | (m) | (m) |
| 2004-10-06 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |